Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 12/20 | 0.54 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286223 | 0.85 | HPGD (0.47) | RIPK2SRCLCKKDRTGFBR1 | |
| SCHEMBL18867444 | 0.85 | HPGD (0.44) | RIPK2SRCLCKKDRTGFBR1 | |
| SCHEMBL18282701 | 0.82 | RIPK2 (0.39) | RIPK2SRCLCKKDRTGFBR1 | |
| SCHEMBL22286138 | 0.80 | MAPK1 (0.53) | SRCHPGDSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7318206 | 0.77 | RIPK2 (0.47) | RIPK2SRCLCKKDRTGFBR1 | |
| SCHEMBL10374185 | 0.76 | RIPK2 (0.37) | RIPK2SRCLCKKDRTGFBR1 | |
| SCHEMBL8357880 | 0.75 | RIPK2 (0.72) | RIPK2SRCLCKKDRTGFBR1 | |
| SCHEMBL2192189 | 0.75 | KDM4E (0.47) | RIPK2KDRHPGDPDPK1ALDH1A1 | |
| SCHEMBL4261283 | 0.73 | RIPK2 (0.70) | RIPK2SRCLCKKDRTGFBR1 | |
| SCHEMBL8308306 | 0.73 | RIPK2 (0.74) | RIPK2SRCLCKKDRTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
| US-5977118-A | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones and compositions and methods of use thereof | SANOFI (FR) | 1999-11-02 | — | — | US | disclosed |
| EP-0813527-A4 | 6-SUBSTITUTED PYRAZOLO 3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP INC (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0813527-A1 | 6-SUBSTITUTED PYRAZOLO 3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5656629-A | CYCLIC GUANOSINE MONOPHSPHATE-PHOSPHODIESTERASE INHIBITOR; USEFUL FOR TREATING HEART FAILURE AND/OR HYPERTENSION | SANOFI WINTHROP, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996028429-A1 | 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | RIPK2 1101/4885SRC 4653/4885LCK 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.